Telix and DuChemBio Announce Korean Partnership for Advanced Prostate Cancer Imaging
Melbourne (Australia) and Seoul (South Korea) – 3rd December 2020. Telix Pharmaceuticals announces it has entered into a licensing and partnership agreement with DuChemBio
Telix is pleased to announce it has entered into a licensing and partnership agreement with DuChemBio, the leading South Korean radiopharmaceutical company, for Telix’s prostate cancer imaging product TLX591-CDx (68Ga-PSMA-11).
Under the terms of the agreement, Telix has granted exclusive rights to commercialise TLX591-CDx for prostate cancer imaging in South Korea.
Telix Pharmaceuticals CEO, Dr. Christian Behrenbruch stated “Telix’s mission is to be a leading global oncology company and South Korea is a key Asian market for our products. We are pleased to have entered this licensing and partnership agreement with DuChemBio to bring this highly anticipated product to Korean men with prostate cancer. DuChemBio has a well-deserved reputation as the number one radiopharmaceutical company in Korea and we look forward to exploring future commercial and clinical opportunities through the experience of this initial partnership.”
Read the full ASX release here.
TLX591-CDx has not received marketing authorisation in any jurisdiction